Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression  by Lu, Xiaoming et al.
ARTICLE
Lupus Risk Variant Increases pSTAT1 Binding
and Decreases ETS1 Expression
Xiaoming Lu,1,2 Erin E. Zoller,2 Matthew T. Weirauch,2,3 Zhiguo Wu,4 Bahram Namjou,2
Adrienne H. Williams,5 Julie T. Ziegler,5 Mary E. Comeau,5 Miranda C. Marion,5 Stuart B. Glenn,6
Adam Adler,6 Nan Shen,2,7 Swapan K. Nath,6 Anne M. Stevens,8,9 Barry I. Freedman,10 Betty P. Tsao,11
Chaim O. Jacob,12 Diane L. Kamen,13 Elizabeth E. Brown,14,15 Gary S. Gilkeson,13 Graciela S. Alarco´n,15
John D. Reveille,16 Juan-Manuel Anaya,17 Judith A. James,6,18 Kathy L. Sivils,6 Lindsey A. Criswell,19
Luis M. Vila´,20 Marta E. Alarco´n-Riquelme,6,21 Michelle Petri,22 R. Hal Scofield,6,18,23
Robert P. Kimberly,15 Rosalind Ramsey-Goldman,24 Young Bin Joo,25 Jeongim Choi,25 Sang-Cheol Bae,25
Susan A. Boackle,26 Deborah Cunninghame Graham,27 Timothy J. Vyse,27 Joel M. Guthridge,6
Patrick M. Gaffney,6 Carl D. Langefeld,5 Jennifer A. Kelly,6 Kenneth D. Greis,28
Kenneth M. Kaufman,2,29 John B. Harley,2,29,30 and Leah C. Kottyan2,29,30,*
Genetic variants at chromosomal region 11q23.3, near the gene ETS1, have been associated with systemic lupus erythematosus (SLE), or
lupus, in independent cohorts of Asian ancestry. Several recent studies have implicated ETS1 as a critical driver of immune cell function
and differentiation, and mice deficient in ETS1 develop an SLE-like autoimmunity. We performed a fine-mapping study of 14,551 sub-
jects from multi-ancestral cohorts by starting with genotyped variants and imputing to all common variants spanning ETS1. By con-
structing genetic models via frequentist and Bayesian association methods, we identified 16 variants that are statistically likely to be
causal. We functionally assessed each of these variants on the basis of their likelihood of affecting transcription factor binding, miRNA
binding, or chromatin state. Of the four variants that we experimentally examined, only rs6590330 differentially binds lysate from B
cells. Using mass spectrometry, we found more binding of the transcription factor signal transducer and activator of transcription 1
(STAT1) to DNA near the risk allele of rs6590330 than near the non-risk allele. Immunoblot analysis and chromatin immunoprecipita-
tion of pSTAT1 in B cells heterozygous for rs6590330 confirmed that the risk allele increased binding to the active form of STAT1. Anal-
ysis with expression quantitative trait loci indicated that the risk allele of rs6590330 is associated with decreased ETS1 expression in Han
Chinese, but not other ancestral cohorts. We propose a model in which the risk allele of rs6590330 is associated with decreased ETS1
expression and increases SLE risk by enhancing the binding of pSTAT1.Introduction
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among monozygotic twins is between 20% and 59%, and
siblings of affected subjects have an 8- to 30-fold higher
risk of developing the disease than the general population.
Recently, several independent genome-wide association
studies (GWASs) in Asian populations have confirmed
that genetic variants in v-ets avian erythroblastosis virus
E26 oncogene homolog 1 (ETS1 [MIM 164720]) are associ-
ated with susceptibility to SLE.6–10 These studies have
established that the most strongly associated SNPs in
ETS1 are rs6590330 and rs1128334.
ETS1 is known to play an important role in regulating
immune cell proliferation and differentiation.11 Moreover,
Ets1-deficient mice develop a lupus-like disease character-
ized by high titers of immunoglobulin M (IgM) and IgG
autoantibodies and immune-complex deposition in the
kidneys.12 Meanwhile, ETS1 mRNA expression levels in
peripheral-blood mononuclear cells (PBMCs) from SLE-
affected individuals are considerably lower than those in
healthy subjects.8 Further, ETS1 mRNA expression in
PBMCs from chromosomes harboring lupus risk alleles is
significantly lower than that in non-risk alleles of healthy
subjects,8 indicating that the risk variants at this locus are
associated with reduced ETS1 expression.
Previous studies have identified genetic association at
ETS1, but no molecular mechanism has been presented
to explain the association. Using a comprehensive dataset
of genetic variants in this region in subjects from multiple
ancestries, we employed frequentist and Bayesian fine-
mapping strategies13 to identify a set of variants that are
likely to be causal.14 This approach resulted in a total of
16 genetic variants comprising our credible set of most
likely causal genetic variants. Importantly, we demon-
strated that the minor allele of rs6590330, the most
strongly associated genetic variant, leads to increased bind-
ing of the activated transcription factor signal transducer
and activator of transcription 1 (pSTAT1), encoded by
STAT1 (MIM 600555), and is correlated with decreased
ETS1 expression. Altogether, our study provides insight
into the mechanism driving the increased lupus risk at
this locus in subjects of Asian ancestry.Material and Methods
Subjects and Study Design
We used a large collection of samples from case and control sub-
jects from multiple ethnic groups (Table S1). These samples were
from the collaborative Large Lupus Association Study 2
(LLAS2)15 and were contributed by participating institutions in
the United States, Asia, and Europe. LLAS2, an SLE genetic-associ-
ation study, used a candidate-gene approach to genotype 347
ancestral-informative markers and 31,851 candidate markers
throughout the genome.16 According to genetic ancestry, subjects
were grouped into four ethnic groups, including European and
European American (EU), African American (AA), Asian and Asian
American (AS), and Hispanic American (HA). All SLE subjects met
the American College of Rheumatology criteria for the classifica-
tion of SLE17 and were enrolled in this study through an732 The American Journal of Human Genetics 96, 731–739, May 7, 2informed-consent process approved by the local institutional re-
view boards.
Genotyping of Genetic Variants and Sample Quality
Control
We genotyped 69 SNPs covering the ETS1 region (spanning 128.2–
128.4 Mb on chromosome 11; GRCh37, UCSC Genome Browser
hg19; Table S1) as part of a larger custom genotyping study. Specif-
ically, the variants were chosen to span the association interval
identified with the Infinium HumanHap330 array of the original
GWAS that identified significant association at this locus. Geno-
typing of SNPs was completed with Infinium chemistry on an
Illumina iSelect custom array according to the manufacturer’s
protocol. The following quality-control procedures were imple-
mented for identifying SNPs for analysis: well-defined clusters
for genotype calling, call rate > 90% across all samples genotyped,
minor allele frequency (MAF)> 0.1%, and p< 0.05 for differential
missingness between case and control subjects. Markers with evi-
dence of a departure from Hardy-Weinberg proportion expecta-
tion (p< 0.0001 in control subjects) were removed from the initial
analysis.
For LLAS2, we removed samples with a call rate < 90% or excess
heterozygosity (the average call rate for ETS1 was 99.3%). The re-
maining individuals were examined for excessive allele sharing
as estimated by identity by descent (IBD). In sample pairs with
excessive relatedness (IBD > 0.4), one individual was removed
from the analysis on the basis of the following criteria: (1) remove
the sample with the lower call rate, (2) remove the control sample
and retain the case sample, (3) remove the male sample before the
female sample, (4) remove the younger control sample before the
older control sample, and (5) in a situation with two case samples,
remove the sample whose available phenotype data are less
complete.
Ascertainment of Population Stratification
Genetic outliers from each ethnic and/or racial group were
removed from further analysis as determined by principal-compo-
nent (PC) analysis and admixture estimates, as previously
described (Figure 1 in Lessard et al.16 and McKeigue et al.18 and
Price et al.19). To distinguish the four continental ancestral popu-
lations, we used 347 ancestry-informative markers (AIMs) that
were from the same custom genotyping study and that passed
quality control in both EIGENSTRAT19 and ADMIXMAP,20,21
allowing identification of the substructure within the sample
set.22,23 The AIMs were selected to distinguish four continental
ancestral populations: Africans, Europeans, American Indians,
and East Asians. We utilized PCs from EIGENSTRAT outputs to
identify outliers of each of the first three PCs for the individual
population clusters with visual inspection.
Statistical Analysis: Workflow
We initiated the analysis by assessing the association of genotyped
variants in each of the four ancestral cohorts individually. Strategi-
cally, we analyzed the genotyped variants and then the imputed
variants, performed full haplotype analysis, executed an analysis
of linkage disequilibrium (LD), and finally built statistical models
to account for the lupus-associated variability in each ancestry
with genome-wide statistical association. In building the one-
SNP models of association in the AS ancestry cohort, we compar-
atively evaluated every possible variant for its ability to account
for the lupus-associated genetic variation.015
Statistical Analysis: Frequentist Approach
We tested each SNP for its association with SLE by using logistic
regression models that included three estimates of admixture pro-
portion as covariates as implemented in PLINK v.1.0724 and
SNPTEST v.2.5.25 The additive genetic model was assessed as the
initially tested model of inheritance for this locus. Other models
were subsequently considered, but these were not found to be sub-
stantially superior.
We performed stepwise logistic regression to identify those sin-
gle-nucleotide variants (SNVs) independently associated with the
development of lupus in PLINK and SNPTEST. For these analyses,
the allelic dosage(s) of specific variant(s), in addition to the admix-
ture estimates, were added to the logistic model as covariates. LD
and haplotypes were determined with Haploview v.4.2.26,27 We
calculated haplotype blocks for those haplotypes present at >3%
frequency by using the four-gamete-rule algorithms with a mini-
mum r2 value of 0.8. We performed haplotypic associations in
PLINK by using a sliding-window approach and assessing the asso-
ciation of haplotypes defined by logistic regression, as described
earlier.Statistical Analysis: Bayesian Approach
Using SNPTEST, we calculated the Bayesian factor (BF) for each
genetic variant: we divided the probability of the genotype
configuration at that genetic variant in case and control subjects
under the alternative hypothesis that the genetic variant was
associated with disease status by the probability of the genotype
configuration at that genetic variant in case and control subjects
under the null hypothesis that disease status was independent of
genotype at that SNP (we used the methods developed and intro-
duced in Maller et al.13 and implemented in Kottyan et al.14). We
used three admixture estimates as covariates, as we did for the fre-
quentist approach. Large BF values correlate with robust evidence
of association, given that small probabilities provide strong evi-
dence in a frequentist approach. For well-powered studies, the
BFs of relatively common variants are highly correlated with
the p values (reviewed in Stephens and Balding28). We used the
additive model. The linear predictor is log(pi / (1  pi)) ¼ m þ
ßGi, and the prior is m ~N(0,1
2), b ~ N(0,0.22) (variables are
defined in SNPTEST and the supplemental note in Maller
et al.13).
To identify the variants most likely to be driving the statistical
association, we calculated a posterior probability under the
assumption that any of the variants within a single genetic effect
could be causal and that only one of these variants was causal for
each genetic effect. Variants with a low posterior probability are
highly unlikely to be causal regardless of the allele frequency or
presence of the actual causal variant in the analysis, according to
the procedure as presented.13 Regardless of whether the causal var-
iants have been genotyped in this experiment, variants with a low
posterior probability are unlikely to be causal.13Imputation to Composite 1000 Genomes Reference
Panel
To detect associated variants that were not directly genotyped, we
imputed the ETS1 region with IMPUTE2 by using a composite
imputation reference panel based on 1000 Genomes Project
sequence data from March 2012.25,29 Imputed genotypes were
included in the analysis if they had or exceeded a probability
threshold of 0.5, an information measure of >0.4, and the same
quality-control criteria described for the genotyped markers. WeThe Amused SNPTEST to incorporate the probability threshold from
each imputed value into the statistical analysis.Electrophoretic Mobility Shift Assay
We annealed pairs of single-stranded 50 IRDye-700-infrared-dye-
labeled 35-bp oligonucleotides (obtained from IDT) to generate
double-stranded probes. We incubated 50 fmol of labeled probes
with nuclear extract prepared from Epstein-Barr-virus-transformed
B cell lines, poly dI-dC (a sodium salt complex of two strands, each
with an alternating sequence of deoxyinosinic acid and deoxycy-
tidylic acid), and buffers supplied by the Odyssey Infrared EMSA
Kit (LI-COR Biosciences) according to LI-COR’s recommended pro-
tocols. The binding reactions were analyzed by electrophoresis on
6% Tris-borate-EDTA polyacrylamide gels and detected by an
infrared fluorescent procedure with the Odyssey Infrared Imaging
System (LI-COR Biosciences). The oligonucleotides sequences are
included in Table S2.DNA Affinity Precipitation Assay
We annealed pairs of single-stranded 50-biotinylated 35-bp oligo-
nucleotides (obtained from IDT) to generate double-stranded
probes. Cell lysates were prepared from Epstein-Barr-virus-trans-
formed B cell lines with cell-lysis buffer supplied by the mMACS
Factor Finder Kit (Miltenyi Biotec) and the addition of protease
inhibitor and phosphatase inhibitors (Pierce Biotechnology).
Binding reactions were then performed with biotinylated probes,
cell lysate, binding buffer, binding enhancer, protease inhibitor,
phosphatase inhibitor, and 0.1 mg poly(dI-dC) according to proto-
cols supplied by the mMACS Factor Finder Kit. Eluted probe-
bounded proteins were identified by Nano liquid chromatography
followed by tandem mass spectrometry analysis30 and immuno-
blotting with anti-STAT1 or anti-pSTAT1 antibodies. The oligonu-
cleotide sequences are included in Table S2.Chromatin Immunoprecipitation qPCR
Crosslinking of protein-chromatin complexes was achieved by in-
cubation of Epstein-Barr-virus-transformed B cells in crosslinking
solution (1% formaldehyde, 5mMHEPES [pH 8.0], 10mM sodium
chloride [NaCl], 0.1 mM EDTA, and 0.05 mM EGTA) and shaking
at room temperature for 10 min. Glycine was added to a final con-
centration of 0.125 M to quench the crosslinking. Cells were
washed twice with ice-cold PBS, resuspended in lysis buffer L1
(50mMHEPES [pH 8.0], 140mMNaCl, 1mMEDTA, 10% glycerol,
0.25% Triton X-100, and 0.5% NP-40), and incubated for 10 min
on ice. Protease and phosphatase inhibitors were added to all
buffers. Nuclei were harvested after centrifugation at 5,000 rpm
for 10 min, resuspended in lysis buffer L2 (10 mM Tris-HCl
[pH 8.0], 1 mM EDTA, 200 mM NaCl, and 0.5 mM EGTA), and
incubated at room temperature for 10 min. Nuclei were resus-
pended in sonication buffer (10 mM Tris [pH 8.0], 1 mM EDTA,
and 0.1% SDS) after centrifuging. A S220 focused ultrasonicator
(COVARIS) was used to shear genomic DNA (150- to 500-bp frag-
ments) with 10% duty cycle, 175 peak power, and 200 bursts per
cycle for 7 min. Sheared chromatin was precleared with 10 ml
Dynabeads Protein G (Life Technologies) at 4C for 1 hr. Antibody
(anti-STAT1, Santa Cruz Biotechnology) was incubated with 20 ml
Dynabeads Protein G at room temperature for 1 hr and then
washed with PBS once. The antibody-coated beads were incubated
with sheared chromatin at 4C overnight. A volume of 1% sheared
chromatin was used as input control. After immunoprecipitation,
the beads were washed consecutively with low-salt wash buffererican Journal of Human Genetics 96, 731–739, May 7, 2015 733
Figure 1. ETS1-Imputed Genetic Variants
Demonstrate Genome-wide Lupus Associ-
ation in a Cohort of Asian Ancestry
Each variant is represented as a data point
in the context of its genomic location
and is colored on the basis of whether it
was directly genotyped (red) or only
imputed (blue). Genomic position is given
with GRCh37 coordinates. rs6590330 was
directly genotyped. The SLE association of
genotyped and imputed variants in co-
horts of Asian and Asian-American (AS)
ancestry (12,57 case and 1,258 control sub-
jects), Hispanic-American (HA) ancestry
(952 case and 335 control subjects), Afri-
can-American (AA) ancestry (1,524 case
and 1,809 control subjects), and European
and European-American (EU) ancestry
(3,926 case and 3,490 control subjects)
were assessed in a logistic regression with
adjustment for admixture estimates.
Genome-wide association was defined as
p < 5 3 108 and is indicated by a dashed
red line in each figure panel.(0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycholate, 1 mM
EDTA, 50 mM Tris-HCl [pH 8], and 150 mM NaCl) twice, high-
salt wash buffer (as above with 500 mM NaCl) twice, LiCl wash
buffer (0.5 M LiCl, 1% NP-40, 0.7% sodium deoxycholate, 1 mM
EDTA, and 50 mM Tris–HCl [pH 8]) twice, and 1 mM EDTA and
10 mM Tris-HCl (pH 8) twice. Purified chromatin fragments were
eluted from the beads with elution buffer (340 mM NaCl, 1 mM
EDTA, and 10 mM Tris-HCl) and 1 mg/ml proteinase K and incu-
bated at 37C for 1 hr. DNA crosslinks were reversed by incubation
of precipitates at 65C for 5 hr. DNA was purified by the PureLink
PCR Micro Kit (Life Technologies) and resuspended in H2O. DNA
was then analyzed by qPCRwith a single set of genotyping primers
and differentially tagged fluorescent probes for the risk and non-
risk alleles of rs6590330. This qPCR was performed by TaqMan
assay on an ABI 7500 PCR system.
For calculating chromatin immunoprecipitation (ChIP) results
as enrichment folds, the amount of immunoprecipitated DNA
from the negative control site and the amount of immunoprecip-
itated DNA from the target site were first normalized against the
amount of input DNA. The enrichment folds were then calculated
as the amount of immunoprecipitated DNA from the target site
divided by the amount of immunoprecipitated DNA from the
negative control site. The sequences of primer pairs and probes
are included in Table S2.Results
Wegenotyped a total of 69 genetic variants in ETS1 in 7,659
SLE subjects and 6,892 control subjects (Table S1). Our
trans-ancestral cohort included AS, HA, EU, and AA partic-
ipants. We then imputed against 1000 Genomes data,
acquiring 1,333 genetic variants with MAFs > 0.01. A total
of 1,402 genetic variants were used for a fine-mapping and
model-building study aimed at identifying the causal ge-
netic variants driving the lupus association at this locus.734 The American Journal of Human Genetics 96, 731–739, May 7, 2We tested each genetic variant individually for its associ-
ation with SLE in each ancestry by using admixture esti-
mates for subjects as covariates (Figure 1). As described in
previous GWASs, the AS ancestry was the only one in
which we identified variants with a probability (p) reach-
ing genome-wide significance (p < 5 3 108) (Figure 1).
Apart from the AS ancestry, we also observed some sugges-
tive association in other ancestries (Figure 1). Before per-
forming this association study, we had enough power to
detect associations with both the AA and EU ancestries
(a prior power of 92% for AA and 99% for EU), whereas
we only had 25% power to detect an association with HA
ancestry. However, HA ancestry had variants with associa-
tion at p < 107, which was reduced to 104 after
admixture adjustment (Figure S1). This suggests that the
association seen in HA ancestry might be due to a mixed
Asian population structure. Therefore, we conclude that
genetic variants in ETS1 are associated with SLE only in
the AS ancestry cohort.
After performing a haplotype association analysis in the
AS ancestry cohort (Table S3), we found that no haplotypic
model of association (plowest ¼ 7.38 3 109) was more sig-
nificant than the SNP rs6590330 (the most significant
SNV; p value ¼ 1.80 3 1011, odds ratio ¼ 1.407 [1.2585–
1.573]), suggesting a single-variant model for lupus risk at
this locus.We then performed a stepwise logistic regression
analysis to identify independent genetic loci in the AS
cohort; we started with adjustment for rs6590330. In the
dataset containing only directly genotyped variants, no
SNP retained a p value < 102 after adjustment for
rs6590330 (Figure 2). Four SNPs retained p values in the
range of 0.001–0.01 after adjustment for rs6590330 with
the full dataset containing both genotyped and imputed
variants. In summary, the great majority of the lupus015
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Figure 2. A Single Genetic Effect Marked
by Genotyped SNV rs6590330 Contrib-
utes to Lupus Risk in the AS Cohort
Genomic position is given with GRCh37
coordinates.
(A) The logistic regression association of
genotyped variants in an AS cohort with
an adjustment for admixture.
(B) The logistic association of genotyped
variants in an AS cohort with an adjust-
ment for admixture and rs6590330.
(C) The logistic association of genotyped
and imputed variants in an AS cohort
with an adjustment for admixture.
(D) The logistic association of genotyped
and imputed variants in an AS cohort
with an adjustment for admixture and
rs6590330.association at this locus was explained by rs6590330.
Therefore, the frequentist approach is consistent with a
model inwhich a single genetic effectmarkedbygenotyped
SNV rs6590330 contributes to lupus risk in our AS cohort.
To complement our frequentist approach, we used a
Bayesian fine-mapping strategy to identify the set of
genetic variants that account for 95% of the total posterior
probability in the region. In total, this procedure was
highly consistent with the frequentist approach and iden-
tified 16 genetic variants (3 genotyped and 13 imputed) as
the 95% credible set that could be responsible for the ETS1
association (Figure 3). These same 16 variants were also
the most highly associated variants in the frequentist
approach. Of the variants evaluated, rs6590330 made a
125-fold greater contribution than any other variant.
Most SNPs in the credible set are in a non-coding region
of the genome, so the way they might act is by affecting
ETS1 expression levels. Yang et al. showed that the risk
allele of rs1128334 is associated with reduced ETS1 mRNA
expression.8 Because rs1128334 is an SNP of the credible
set, and is in high LD with the other 15 SNPs, we hypothe-
sized that each of the SNPs in the credible set was associated
with reduced ETS1 expression. We confirmed this hypoth-
esis that members of the candidate credible set were associ-
ated with ETS1 expression by using publically available
SNP-mRNA expression data. For example, we found that
rs6590330 is a strong expression quantitative trait locus
(eQTL) for ETS1, given that the risk allele is associated
with reduced ETS1 expression in HapMap subjects from
the China-Beijing cohort (Figure S2). Meanwhile, this SNP
is also found to be a significant eQTL for nearby gene
TP53AIP1 (MIM 605426), suggesting the potential for mul-
tiple genotype-dependent changes in gene expression at
this locus (Figure S2).The American Journal of HumaOn the basis of our analysis, we hy-
pothesized that the causal variant
might reduce ETS1 expression
through differential miRNA bind-
ing, differential transcriptional factor
binding, and/or changing chromatininteraction(s) or state(s). We used datasets and tools avail-
able from TargetScan,31 Cis-BP,32 Roadmap Epigenomics,33
ENCODE,34 and other sources to assess these possibilities
for each of the SNVs in the credible set. The non-risk allele
of rs1128334 was predicted to be bound by miR-300;31,35
however, miR-300 is not expressed in cells of hematopoi-
etic origin. The other 15 variants were not located within
the ETS1 transcript and thus were not predicted to
disrupt miRNA binding. Altogether, we identified four
promising functional variants with experimental evidence
suggesting that they might affect transcription factor
binding by locating to active chromatin regions. These
four variants were identified according to the chromatin-
state-segmentation hidden Markov model from the Road-
map Project,33 chromatin looping to RNA polymerase II,36
and DNase hypersensitivity clusters (Figure S3). We then
experimentally analyzed these four most promising vari-
ants for differential transcriptional factor binding between
risk and non-risk alleles with electrophoretic mobility
shift assays using nuclear lysate from B cells (Figure S4).
Of these variants, only rs6590330 exhibited differential
binding of the risk and non-risk oligonucleotides to nu-
clear factors (Figure S4). For this variant, we identified
the specific differentially bound protein by using a DNA
affinity precipitation assay (DAPA) followed by mass spec-
trometry. The mass spectrometry results indicated that
STAT1 binds to the risk allele but not the non-risk allele
for rs6590330 (Table S4). We confirmed this finding by
DAPA followed by immunoblotting for phosphorylated
STAT1 and total STAT1 (Figure 4). Critically, STAT1 ChIP-
qPCR analysis also confirmed that the risk allele of
rs6590330 has more STAT1 binding enrichment than the
non-risk allele in B cells heterozygous for rs6590330
(Figure 4).n Genetics 96, 731–739, May 7, 2015 735
Figure 3. Bayesian Association Plot Showing the Signal
Strength in ETS1 as the Posterior Probability of Each SNV
Genomic position is given with GRCh37 coordinates; AS data are
shown. SNVs are colored according to their origin: genotyped var-
iants are in red, and imputed variants are in blue. Variants in the
95% credible set aremarked by diamonds. Variants with larger pos-
terior probabilities (>0.01) represent thosemost likely to be causal.
A
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Figure 4. The Lupus Risk Allele of rs6590330 Increases STAT1
Binding
(A) STAT1 and pSTAT1 exhibit higher binding to oligonucleotides
containing the rs6590330 risk allele than to oligonucleotides con-
taining the non-risk allele. Biotin-labeled oligonucleotides were
incubated with nuclear extract from Epstein-Barr-virus-trans-
formed B cells. Proteins bound to the oligonucleotides were
captured with the mMACs Factor Finder Kit. Proteins were then
separated by SDS-PAGE and detected with anti-pSTAT1 (top) and
anti-STAT1 (bottom). Abbreviations are as follows: M, marker;
NR, oligonucleotide containing the non-risk allele of rs6590330;
R, oligonucleotide containing the risk allele of rs6590330 (see
Figure S5); mutant, oligonucleotide containing a disrupted puta-
tive STAT binding site downstream of rs6590330; and cell lysate,
nuclear extract from B cells. The relative intensities of the bands
are given above each band. Results are representative of four exper-
iments; although all experiments demonstrated increased STAT1
binding to the probes with the risk allele, in two of four experi-
ments, no STAT1 or pSTAT1 was detected in the immunoprecipi-
tate from the non-risk oligonucleotide, whereas both were
detected in the immunoprecipitate from the risk oligonucleotide.
(B) rs6590330-heterozygous Epstein-Barr-virus-transformed B cells
were used for ChIP-qPCR assessment of the differential binding of
STAT1 to the risk and non-risk alleles. Crosslinked and sonicated
chromatin was immunoprecipitated with an anti-STAT1 antibody.
Site-specific primers and probes specific to the rs6590330 risk and
non-risk alleles were used for determining STAT1 binding to
immunoprecipitated DNA.rs6590330 is located 11 bases away from a putative
STAT1 binding site predicted by a bindingmodel identified
in Factorbook37 (Figure S5). When this STAT binding site
was disrupted in the oligonucleotide used for the DAPA
analysis containing the risk variant, the binding of STAT1
was also disrupted (Figure 4). STAT1 can be activated by
type I interferons, including interferon alpha. In the
context of data supporting chromatin looping of DNA sur-
rounding rs650330 to the ETS1 transcription start site, it is
possible that this variant enhances activated STAT1 bind-
ing to the putative STAT1 binding site near rs6590330
and thus results in the repression of ETS1 transcription
initiated by RNA polymerase II. Taken together, these re-
sults strongly support a model in which the variant
rs6590330 is highly associated with decreased expression
of ETS1 and increased lupus risk through pSTAT1 binding
of a DNA sequence located next to the risk allele in B cells.736 The American Journal of Human Genetics 96, 731–739, May 7, 2Discussion
The genotyped and imputed data from 14,551 subjects
facilitated fine mapping of ETS1 and its association with
SLE risk. A model consisting of a single genetic effect
was identified by stepwise logistic regression analyses.015
Importantly, a set of 16 variants that are likely to be causal
were identified through frequentist and Bayesian analyses.
Our data are consistent with amechanistic model in which
the risk allele of rs6590330 at ETS1 contributes to increased
SLE risk by facilitating binding of pSTAT1 to a nearby puta-
tive STAT binding site and subsequent repression of the
expression of ETS1. Our fine-mapping results are corrobo-
rated by a recent study that used a different analytical
method to estimate the probability that each variant
within ETS1 is a causal variant; this study concluded that
rs6590330 is among the most likely causal variants pro-
posed for the ETS1 association with SLE,38 further support-
ing the results of our genetic analysis.
The biological mechanism we propose herein is specific
to the association of ETS1 variants in the AS cohort. We
performed the functional validation in B cells on the basis
of the evidence that B cells play a critical role in the etiol-
ogy of SLE. Previous studies have demonstrated that B cells
are significantly enriched with the expression of genes
near lupus risk loci.39 Meanwhile, B cells from lupus-
affected individuals produce autoantibodies, are hyperacti-
vated, and have an exaggerated response to Toll-like
receptor ligands and immune complexes.40 ETS1-hypo-
morphic mice (producing ETS1 lacking the Pointed
domain [Ets1p/p]) develop a strikingly similar B cell pheno-
type.12,41 This ETS1 deficiency has been shown to drive
intrinsic terminal differentiation of B cells into IgM-
secreting plasma cells in a B-cell-intrinsic fashion.42
Although we limited our functional analysis to B cells, it re-
mains possible that the same genetic risk mechanism
might also operate in other cell types, such as T cells.42,43
In all four ancestries, rs6590330 is polymorphic (MAFAS¼
45%, MAFAA ¼ 31%, MAFHA ¼ 28%, and MAFEU ¼ 26%).
The ETS1 associationhas only been observed in AS ancestry
cohorts in our study and others before us. Perhaps ETS1 var-
iants do not increase SLE risk in AA and EU populations, a
possibility consistent with epistasis or environmental fac-
tors (gene-environment interactions).44 Asian-specific vari-
ants have been identified in previous studies,1,10 and it is
not surprising that ancestry-specific genetic factors affect
the risk of SLE. Subjects of Asians ancestry have a higher
SLE incidence than do those of European ancestry, in
addition to an ancestry-specific distribution of clinical
manifestations.45
We found that the risk allele of rs6590330 results in pref-
erential binding of pSTAT1 to a nearby putative STAT bind-
ing site and is associated with reduced expression of ETS1.
STAT1 plays a complex role in regulating gene expression
and is capable of acting as either an activator or a repressor,
depending on the cellular context.46 This is an intriguing
candidate causal mechanism in which disease risk is medi-
ated through the disruption of transcription factor binding
to a nearby site that does not contain the risk variant.
Because the risk allele of rs6590330 is associated with
reduced ETS1 expression (Yang et al.8 and Figure S2), it is
possible that reduced ETS1 expression associated with
the risk allele of rs6590330 might skew B cell differentia-The Amtion to IgM plasma cells and thus subsequently contribute
to SLE pathogenesis. Meanwhile, even though we present
rs6590330 as a candidate causal variant responsible for dis-
ease risk, more experiments are necessary to establish cau-
sality and define the genotype-dependent immunological
mechanisms driving lupus at this locus.
In conclusion, we conducted a large trans-ancestral fine-
mapping study of ETS1 to identify genetic variants that
increase lupus risk. After determining a model of single ge-
netic effect, we used frequentist and Bayesian association
methods to identify a set of 16 variants that are most likely
causal. Of these, we identified an allele-specific function
for rs6590330. Altogether, we propose a model in which
the risk allele of rs6590330 increases SLE risk through
increased binding of pSTAT1 and depressed expression
of ETS1.Supplemental Data
Supplemental Data include five figures and four tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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